ProCE Banner Activity

My Take on the Recent Approval of Dual Immune Checkpoint Inhibition for Advanced NSCLC

Clinical Thought
The combination of nivolumab and ipilimumab, with or without chemotherapy, is now approved for advanced NSCLC. Read my thoughts on the rationale for these approvals and how to integrate these regimens into clinical practice.

Released: July 06, 2020

Expiration: July 05, 2021

No longer available for credit.

Share

Faculty

Stephen Liu

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Celgene

Loxo Oncology subsidiary of Eli Lilly

Partners

GRACE

ProCE Banner

Faculty Disclosure

Primary Author

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Stephen V. Liu, MD, has disclosed that he has received funds for research support from Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Corvus, Genentech/Roche, Lilly, Lycera, Merck/MSD, Merus, Molecular Partners, Pfizer, Rain Therapeutics, RAPT, Spectrum, and Turning Point; consulting fees from AstraZeneca, Bristol-Myers Squibb, Catalyst, Celgene, G1 Therapeutics, Genentech/Roche, Guardant, Inivata, Janssen, Lilly, Merck/MSD, Pfizer, PharmaMar, Regeneron, and Takeda; and other financial or material support from Boehringer Ingelheim.